Data Processing Systems And Methods For Providing Training In A Vendor Procurement Process”

 

2022 NOV 24 (NewsRx) -- By a News Reporter-Staff News Editor at Insurance Daily News -- A patent application by the inventors Barday, Kabir A. (Atlanta, GA, US); Brannon, Jonathan Blake (Smyrna, GA, US), filed on July 20, 2022, was made available online on November 10, 2022, according to news reporting originating from Washington, D.C., by NewsRx correspondents.

This patent application is assigned to OneTrust LLC (Atlanta, Georgia, United States).

The following quote was obtained by the news editors from the background information supplied by the inventors: “Over the past years, privacy and security policies, and related operations have become increasingly important. Breaches in security, leading to the unauthorized access of personal data (which may include sensitive personal data) have become more frequent among companies and other organizations of all sizes. Such personal data may include, but is not limited to, personally identifiable information (PII), which may be information that directly (or indirectly) identifies an individual or entity. Examples of PII include names, addresses, dates of birth, social security numbers, and biometric identifiers such as a person’s fingerprints or picture. Other personal data may include, for example, customers’ Internet browsing habits, purchase history, or even their preferences (e.g., likes and dislikes, as provided or obtained through social media).

“Many organizations that obtain, use, and transfer personal data, including sensitive personal data, have begun to address these privacy and security issues. To manage personal data, many companies have attempted to implement operational policies and processes that comply with legal requirements, such as Canada’s Personal Information Protection and Electronic Documents Act (PIPEDA) or the U.S.’s Health Insurance Portability and Accountability Act (HIPPA) protecting a patient’s medical information. Many regulators recommend conducting privacy impact assessments, or data protection risk assessments along with data inventory mapping. For example, the GDPR requires data protection impact assessments. Additionally, the United Kingdom ICO’s office provides guidance around privacy impact assessments. The OPC in Canada recommends certain personal information inventory practices, and the Singapore PDPA specifically mentions personal data inventory mapping.

“In implementing these privacy impact assessments, an individual may provide incomplete or incorrect information regarding personal data to be collected, for example, by new software, a new device, or a new business effort, for example, to avoid being prevented from collecting that personal data, or to avoid being subject to more frequent or more detailed privacy audits. In light of the above, there is currently a need for improved systems and methods for monitoring compliance with corporate privacy policies and applicable privacy laws in order to reduce a likelihood that an individual will successfully “game the system” by providing incomplete or incorrect information regarding current or future uses of personal data.

“Organizations that obtain, use, and transfer personal data often work with other organizations (“vendors”) that provide services and/or products to the organizations. Organizations working with vendors may be responsible for ensuring that any personal data to which their vendors may have access is handled properly. However, organizations may have limited control over vendors and limited insight into their internal policies and procedures. Therefore, there is currently a need for improved systems and methods that help organizations ensure that their vendors handle personal data properly. There is also a need for improved systems and methods for estimating the timing of vendor risk analysis and procurement and providing effective training to ensure that employees and/or vendors are compliant with applicable privacy and security regulations and standards.”

In addition to the background information obtained for this patent application, NewsRx journalists also obtained the inventors’ summary information for this patent application: “According to various aspects, a method is provided that comprises: detecting, by computing hardware, a request to procure a vendor for an entity and a user parameter identifying a user, wherein the vendor is to provide at least one of a service or a product to the entity; determining, by the computing hardware and based on an assessment conducted on the vendor with respect to the vendor handling data for the entity, a training requirement associated with a procurement of the vendor; determining, by the computing hardware and based on the user parameter and training data for the user, a progress of the user completing the training requirement; generating, by the computing hardware and based on the progress of the user, customized training content comprising a portion of a training course associated with the training requirement; and configuring, by the computing hardware, a graphical user interface to display a presentation element configured for presenting the customized training content on the graphical user interface.

More info : 

Embedded AI Localizes Data Processing for Greater Speed and Security

The Fraunhofer Institute for Photonic Microsystems (IPMS) aims to support more secure, faster data processing by integrating machine learning algorithms into digital devices.

Although AI-enabled devices are firmly integrated with daily life, the processing of data inputs takes place on large, external servers. Embedded artificial intelligence (edge AI) is poised to change this by allowing those processing tasks to take place directly on the device. However, the performance of AI, especially in very small devices, has so far been/

The researchers at Fraunhofer IPMS are working to remedy this by networking expertise and developments from disparate research areas. For example, in an internal institute project, findings from microsensor and actuator technology were combined with the latest technologies in nanoelectronics, wireless communication, and processor developments.


The combination enables sensor- or actuator-related signal preprocessing using AI-based methods, providing advantages in low latency processing and more secure data processing while eschewing the need for network connectivity. Additionally, the use of edge AI to process data would enable re-learning locally in the field, so that the system could be optimized for specific on-site boundary conditions.

More info : 

Real world data: new horizons for data processing in healthcare

Real World Data (RWD) are becoming one of the most crucial issues in the Italian health sector. There is no doubt that the current digitisation of health services, expected to expand even more with the PNRR (Recovery and Resilience Plan) will lead to a significant production of digital data in healthcare.

Such data originates from patient care, but apart from being used in clinical settings and/or for the improvement of drugs and devices, it can also play a key role in system governance.

This is why the Note 'Observational research: a pillar in the knowledge production process' published by the Italian National Coordination Centre of Ethical Committees (CCNCE), set up at AIFA, the Italian Medicines Agency, deserves in-depth analysis.

How the Note was created

The CCNCE Note originates under Decree 30 November 2021 - Measures to facilitate and support the conduct of non-profit clinical trials of medicinal products and observational studies and to regulate the transfer of data and results of non-profit trials for registration purposes, pursuant to Article 1, para. 1, letter c) of Leg. Decree 14 May 2019, no. 52: what people in the field call more concisely, "Decreto cessione dati” (Data Transfer Decree).

This Decree, in addition to establishing how data collected within the scope of a non-profit clinical trial can be transferred, also paves the way for a redefinition and rethinking of the complex field of so-called 'observational studies' in the light of the new EU framework as defined by EU Reg. 2014/536.

More precisely, the Decree (implementing Art. 6 para. 6-ter of Legislative Decree 200/2007 as amended by Leg. Decree 52/2019) states that:‘observational studies’ means “studies referred to in Article 2, paragraph 2, point 4 of EU Reg. 2014/536, the subject of the protocol being the study of drugs in the normal clinical practice in accordance with the authorised indications. Observational studies may be either non-profit or for-profit” – Article 1(4)(c) of Decree 30 November 2021
the new guidelines for the classification and carrying out of observational studies on drugs are defined by AIFA.

Moreover, the CCNCE Note introduces considerations and indications regarding a particular and more specific 'category' of observational studies: those in which the health professional (researcher) merely records what is happening in actual reality. So it reads:

"This paper is concerned with observational studies understood as studies characterised by the absence of active intervention on the part of the researchers, thus defined here as studies in which the researcher does not determine the assignment of subjects to the different study groups, but merely records (observes) what happens in reality".

Basically, in these studies there is no clinical protocol with an end point, but merely the observation, collection and recording of data emerging from everyday reality.

The term Real World Data is not directly used, but that is the meaning that the wording points to. In fact, on the Digital Health Europe website, RWD are defined as follows:

“Real world data is big data, referring specifically to any type of data not collected in a randomised clinical trial. This data can complement randomised clinical trial data to fill the knowledge gap between clinical trials and clinical practice, provide new insights into disease patterns and help improve the safety and effectiveness of health interventions (EU definition)”.

What the Note states

Having clarified the scope of application, let us see what the Note states, particularly in relation to data processing.

The National Coordination Centre recommends first and foremost that the Ethics Committees adopt an attitude of maximum simplification of obligations related to data protection "...by removing or reducing as much as possible the formal obstacles that an interpretation of the legislation, based on a predominantly 'interventionist' and 'single-use' approach, still poses to the use and re-use of research data".

Data re-use is not prohibited

In essence, the direction is to simplify and realise that the reuse of data is not prohibited. It is here that the first great opening, also from a cultural point of view, can be found.

In fact, it is well known that Article 6(4) GDPR expressly admits the possibility of re-using data for a purpose other than that for which the data were collected, provided that the use is assessed as 'compatible' with the original purpose. Article 5(b) also establishes, in particular, a sort of presumption of non-incompatibility for a secondary use for scientific research purposes.

It is equally known that in Italy this legal opening introduced by the GDPR is severely limited by Article 110-bis of the Privacy Code, which binds data re-use to an authorisation by the Data Protection Authority, which may be specific or have a general nature (Article 110-bis(3)).

Now, apart from the fact that an authorisation regime seems to defeat the underlying philosophy and logic of the GDPR, which is based on the principle of accountability, there is some interpretative confusion because it is not clear (and is being debated among insiders) whether Measure No. 101 of 10 August 2018 issued by the Italian DPA on the processing of special categories of data (especially the part concerning Scientific Research) can be considered a general provision legitimising the re-use of data pursuant to Article 110-bis. This is in view of the fact that it represents the evolution of the previous Authorisation 9/2016, which is certainly general in scope, which implements Article 21 Leg. Decree 101/2018 and which is published in the Official Gazette. Our personal opinion is that it can be considered a general authorisation, but we are not aware of any position of the DPA to that effect and therefore public facilities are all very reluctant in this regard.

In this respect, the Note, while certainly not overriding the legislative text outright, does however strongly urge the legislator to revise the entire matter in a much less restrictive sense, also highlighting the importance of data re-use for the country and pushing for an interpretation that favours such re-use.

Legitimate interest as a legal basis

The second major opening of the Note concerns the legal basis: it is stated that data re-use can also have its legal basis in legitimate interest (Art. 6(1)(f) GDPR). The legal reasoning supporting this is very interesting:

"as a 'source' of significant knowledge for the scientific community, such data must be able to circulate as freely as possible within it. Particularly when the purposes of the research are observational (in the sense considered here), it should be possible to use alternative legal bases to facilitate the (re)processing of the data, without having to rely each time on a new consent of the data subject. The only limitation would be a prior and appropriate pseudonymisation/encryption of the patient's identity, thus reasonably and effectively balancing the "right of the individual and the interest of the general public" (Article 32 of the Italian Constitution).

Also: “from this point of view, a reference to legitimate interest as a possible legal basis for processing could, within the limits seen above, benefit the advancement of observational research”.

Here that sort of implicit obligation to use consent as a legal basis always and in all cases is challenged, probably for the first time by an institutional body of this level, paving the way for other legal bases (moreover, it is highly debatable whether consent can be considered truly 'free' for this type of processing).

On legitimate interest, there is one final point to be made.

This legal basis (in combination with one of the exceptions in Art. 9) may in some respects simplify the procedure with respect to consent, but it still requires other (and higher) levels of caution. It can in fact be lawfully used only after a so-called balancing of interests has been carried out.

On this subject, the judgment of the Court of Justice (Second Chamber) of 4 May 2017 - C-13/16 established a three-step test:the existence of an interest on the part of the data controller must be established,
the processing of that data must be necessary in order to serve that interest;
the interest of the data controller must prevail over that of the data subject (balancing of interests). Thus, processing cannot be justified (lawful) if it entails detrimental effects on the rights and freedoms or legitimate interests of the individual.

Each stage consists of a separate assessment from the others.

Why this Note is so important

This note is so significant because it was issued by the national coordinating body of the Ethics Committees: it is clear that the Committees can decide independently, but it is equally true that this is a very strong input.

The scope is clear if one looks at the path that Europe has taken with the European Data Strategy and, in particular, in the architecture of the Proposal of regulation of the European Parliament and of the Council on the European Health Data Space.

In this context, the value of real-world data is indisputably revealed in the recent EU document Study on the use of real-world data (RWD) for research, clinical care, regulatory decision-making, health technology assessment, and policymaking (2021).

It is precisely because of this value and scope that we cannot lag behind.

More info : 

Automatic Data Processing (NASDAQ:ADP) Price Target Raised to $276.00 at Mizuho

 

 

Automatic Data Processing (NASDAQ:ADP - Get Rating) had its price target lifted by analysts at Mizuho from $257.00 to $276.00 in a research note issued to investors on Friday, The Fly reports. Mizuho's price objective would suggest a potential upside of 5.11% from the company's current price.

Other research analysts also recently issued reports about the stock. StockNews.com downgraded shares of Automatic Data Processing from a "buy" rating to a "hold" rating in a research note on Thursday, November 17th. Cowen upped their target price on shares of Automatic Data Processing to $237.00 in a research note on Thursday, October 27th. Barclays upped their target price on shares of Automatic Data Processing to $280.00 in a research note on Tuesday, August 9th. Cowen upped their target price on shares of Automatic Data Processing from $230.00 to $236.00 in a research note on Tuesday, September 20th. Finally, Robert W. Baird upped their target price on shares of Automatic Data Processing to $251.00 in a research note on Tuesday, November 1st. Six research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $242.27.


ADP opened at $262.58 on Friday. The company has a quick ratio of 0.97, a current ratio of 0.97 and a debt-to-equity ratio of 1.16. Automatic Data Processing has a 52-week low of $192.26 and a 52-week high of $264.00. The company has a 50 day moving average of $237.94 and a two-hundred day moving average of $230.58. The company has a market cap of $108.93 billion, a P/E ratio of 36.32, a P/E/G ratio of 2.69 and a beta of 0.82

More info : 

Glaring gaps, missing pieces in draft data protection bill .

 

Glaring gaps, missing pieces in draft data protection bill.

The Ministry of Electronics and Information Technology (MeitY), on November 18, released a draft Digital Personal Data Protection Bill.

for more info :  

www.dprg.co.in

Global Data Processing Unit Market to Reach $5.5 Billion by 2031: Allied Market Research

 

Rise in internet penetration, surge in penetration of high-end cloud computing in enterprise, rise in data center complexities due to scalability, growth in the popularity of 5G network capabilities, and persistent technological advancements to drive the global data processing unit market growth. Closure of production and manufacturing facilities, shortage of skilled workforce, and other supply chain challenges during the pandemic had a negative impact on the global market.Portland, OR, Oct. 21, 2022 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global data processing unit market generated $553.96 million in 2021, and is projected to reach $5.5 billion by 2031, growing at a CAGR of 26.9% from 2022 to 2031. The report offers a detailed analysis of the top winning strategies, evolving market trends, market size and estimations, value chain, key investment pockets, drivers & opportunities, competitive landscape and regional landscape. The report is a useful source of information for new entrants, shareholders, frontrunners and shareholders in introducing necessary strategies for the future and taking essential steps to significantly strengthen and heighten their position in the market.

More info: 

MUHS inaugurates first genetic lab-cancer research centre in Pune

In a welcome move, the Maharashtra University of Health Sciences (MUHS) on Friday inaugurated its first genetic laboratory and cancer research centre in the city – MUHS Genehealth – that will conduct medical tests for citizens at affordable rates with additional discounts to patients from poor financial backgrounds. The lab was inaugurated at the hands of Bhagat Singh Koshyari, governor of Maharashtra. “Various tests will be conducted through this genetic lab. It will benefit society at large. The government is implementing various programmes to provide low-cost health services to people living in remote places,” Koshyari said.

At a press interaction during inauguration of the centre, MUHS vice-chancellor Lt gen (retd.) Madhuri Kanitkar said that the facility will help patients from economically weaker sections to get better genetic testing facilities. “We will be starting the facility from December onwards. We are slowly going to rollout testing from that for sickle cell anaemia to other diseases. These patients can come to us with a referral from government hospitals and government medical colleges, and get treatment,” said Kanitkar. The lab will also host a variety of skill-based courses for students, she added.

“We are also beginning certificate courses for students. We are likely to expand the variety of courses in genetic and molecular diagnostics. Our aim is to expand these certificate courses so that they are internationally recognised,” said Kanitkar.

More info: 

MLA seeks turmeric research centre

 

Modakurichi MLA Dr CK Saraswathi submitted a memorandum to the CM at the secretariat on Tuesday regarding many demands for the development of her segment. She was accompanied party leaders Pon Radhakrishnan and Nainar Nagendran.

The demands are: allotmet of 10 acre Boodhan land at Vadugapatti for establishing a turmeric research centre. As land is available at Basur Kilambadi, Kendriya Vidya School can be established there with building temporary class rooms.

Jaljeevan Mission

Allotment of fund to remove bushes and encroachments in Anuman River and fund to renovate travellers bungalow at Kodumudi without affecting its heritage importance after getting the advice of archaeological department. Relaying roads damaged due to laying pipeline under Jaljeevan Mission. Establishment of sub-registrar office in Modakurichi Taluk.

Construction of new classrooms in government schools replacing old buildings. Upgradation of Chozhasiramani-Basur-Ezhumathur-Perundurai road as state highways. The road between RD school railway bridge to Panjalingapuram bridge should be lined up without curvings. DSP office at Modakurichi with creating separate police division. Adequate Infrastructure in all primary health centres.

More info :